Showing 5061-5070 of 5621 results for "".
- Intravitreous Ranibizumab Cost-Effective for Some With Proliferative Diabetic Retinopathyhttps://modernod.com/news/intravitreous-ranibizumab-cost-effective-for-some-with-proliferative-diabetic-retinopathy/2477079/At 5 years, intravitreous ranibizumab therapy for proliferative diabetic retinopathy (DR) appears to be cost-effective relative to panretinal photocoagulation (PRP), but only in eyes with vision-impairing center-involved diabetic macular edema (CI-DME), according to new findings
- Optina Diagnostics and Wagner Macula Retina Center to Conduct a Study to Identify the Causes of Memory Loss Through Eye Diagnosticshttps://modernod.com/news/optina-diagnostics-and-wagner-macula-retina-center-will-collaborate-to-conduct-a-clinical-study-to-identify-the-causes-of-memory-loss-through-eye-diagnostics/2477076/Optina Diagnostics and Wagner Macula Retina Center are entering into a collaboration agreement to conduct a clinical study for the advancement of Optina’s Retinal Deep Phenotyping platform. This collaboration will lay the groundwork for Optina’s future pivotal clinical trial. &
- Vision Plan Customer Satisfaction Increases, J.D. Power Findshttps://modernod.com/news/vision-plan-customer-satisfaction-increases-j-d-power-finds/2477073/Overall customer satisfaction among vision plan members has increased in 2019, driven by improved perceptions of value and coverage. According to the J.D. Power 2019 Vision Plan Satisfaction Report, overall satisfaction increased by 17 points (on a 1,000-point scale) to 770 this year from 753 in
- AGTC Announces Stargardt Disease as its Second Preclinical Ophthalmology Programhttps://modernod.com/news/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program/2477071/Applied Genetic Technologies Corporation (AGTC), announced that it has identified Stargardt disease as the second ophthalmology program in its previously announced preclinical pipeline expansion, which also includes a program targeting the dry form of age-related macular degenerat
- Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil in Phase 2 Study Conducted in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-topline-results-for-netarsudil-in-phase-2-study-conducted-in-japan/2477069/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating netarsudil ophthalmic solution in Japanese patients. Netarsudil is a Rho kinase (ROCK) inhibitor specifically designed to increase outflow of aqueous humor through the trabecular meshwork,
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Johnson & Johnson Vision Launches Tecnis Eyhance Monofocal IOL in Indiahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-eyhance-monofocal-iol-in-india/2477059/Johnson & Johnson Vision announced the launch of Tecnis Eyhance IOL, which is designed to extend depth of focus from distance to intermediate vision. Over the past several decades, India’s eye care system has made tremendous strides towards high q
- EyePrint Prosthetics Releases New Scleral Lens Technology: ScanFitPROhttps://modernod.com/news/eyeprint-prosthetics-releases-new-scleral-lens-technology-scanfitpro/2477058/EyePrint Prosthetics has announced the development of its new scleral lens fitting software, ScanFitPRO. This new technology simplifies every-day contact lens fitting by employing EyePrint Prosthetic’s scleral lens designer algorithm to automatically design a lens in 3-dimensional space, accordin
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipelinehttps://modernod.com/news/eyenovia-advances-microline-for-the-treatment-of-presbyopia-reprioritizes-late-stage-ophthalmology-pipeline/2477052/Eyenovia announced that the company is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia toward phase 3 development. As a result of prioritizing MicroLine in tandem with its MicroPine (progressive myopia) and MicroSta